跳到正文
原文
Medical Xpress·· 7 天前AI 评分56

类风湿性关节炎中神经免疫调节疗法维持临床疗效

Sustained clinical responses seen with neuroimmune modulation for rheumatoid arthritis

AI 导读

一项24个月的随机对照试验显示,类风湿性关节炎患者在接受神经免疫调节疗法后,临床疗效持续存在,ACR20、ACR50和ACR70反应率分别为57.7%、43.6%和25.5%。

正文
rheumatoid arthritis
Credit: Unsplash/CC0 Public Domain

Twenty-four-month data show sustained clinical responses for patients receiving neuroimmune modulation therapy for rheumatoid arthritis (RA), according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 6 to 11 in Orlando, Florida.

John Tesser, M.D., from Arizona Arthritis & Rheumatology Associates in Phoenix, and colleagues reported long-term safety and efficacy outcomes at 24 months in a randomized pivotal trial.

Patients with RA with an inadequate response or intolerance to at least one biological or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) were enrolled; all patients received neuroimmune modulation using an implantable device to deliver a one-minute daily dose of electrical stimulation to the left cervical vagus nerve during open-label extension.

A total of 242 patients across 41 sites underwent device implantation.

The researchers found that 92.1% of the patients continued with stimulation therapy at 24-month follow-up; 62.8% had not added a b/tsDMARD to stimulation therapy. The ACR20 (≥20% improvement) rate was 57.7%, 62.1% and 70.9% at 12, 18 and 24 months, respectively, for stimulation therapy without add-on therapy.

At 24 months, the ACR50 rate was 43.6% and the ACR70 rate was 25.5%; low disease activity or remission was attained by 54.6% and 55.0% by the Disease Activity Score 28 using C-reactive protein and by the Clinical Disease Activity Index, respectively. Overall, 80.6% met the European Alliance of Associations for Rheumatology good or moderate response.

"The findings further validate SetPoint neuroimmune modulation therapy as a differentiated treatment approach for those living with rheumatoid arthritis," coauthor David Chernoff, M.D., from SetPoint Medical in Sausalito, California, said in a statement.

Clinical categories

Rheumatology

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Copyright © 2026 HealthDay. All rights reserved.

Citation: Sustained clinical responses seen with neuroimmune modulation for rheumatoid arthritis (2026, November 13) retrieved 13 November 2026 from https://medicalxpress.com/news/2026-11-sustained-clinical-responses-neuroimmune-modulation.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com